Dergiler / Balkan Medical Journal / 2015 / Cilt: 32 - Sayı: 2

The Effects of sugammadex on progesterone levels in pregnant rats

Sayfa
203–207
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Successful completion ofpregnancy and the absence of stillbirth or miscarriagewill guide future studies about the use of sugammadex,particularly in the first trimester of the pregnancy.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Sugammadex has been shown to de- crease the efficiency of progesterone-containing oralcontraceptive drugs which possess a steroid structure.
📊
Temel Bulgular & Veri:Pregnant Winster Albino rats (n=26) weredivided into three groups and administered with vari- ous intravenous injections on the 7th day of pregnancy.The control group (Group K, n=6) received 1.5 mLserum physiologic, the sugammadex group (Group S,n=10) received 30 mg/kg sugammadex and the sugam- madex + rocuronium group (Group SR, n=10) received30 mg/kg sugammadex and 3.5 mg/kg rocuronium.
💡
Sonuç & Katkı:Successful completion ofpregnancy and the absence of stillbirth or miscarriagewill guide future studies about the use of sugammadex,particularly in the first trimester of the pregnancy.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background: Sugammadex has been shown to de- crease the efficiency of progesterone-containing oralcontraceptive drugs which possess a steroid structure. Aims: The aim of the present study was to evaluatethe effects of sugammadex on progesterone levels inpregnant rats as well as on the physiological course ofthe pregnancy. Study Design: Animal experiment. Methods: This study was approved by the Selçuk Uni- versity Ethical Committee for Experimental AnimalResearch. Pregnant Winster Albino rats (n=26) weredivided into three groups and administered with vari- ous intravenous injections on the 7th day of pregnancy.The control group (Group K, n=6) received 1.5 mLserum physiologic, the sugammadex group (Group S,n=10) received 30 mg/kg sugammadex and the sugam- madex + rocuronium group (Group SR, n=10) received30 mg/kg sugammadex and 3.5 mg/kg rocuronium. Progesterone levels were measured and the offspringwere monitored for morphologic status.Results: Mean progesterone levels were 94.16±15.54ng/mL in Group K, 87.86±12.48 ng/mL in Group S,and 94.53±16.10 ng/mL in Group SR (p>0.05). Nostillbirth or miscarriage was observed in the rats. Themean number of offspring was 6.8±1.47 in Group K,6.5±1.35 in Group S, and 6.4±1.17 in Group SR. Theoffspring appeared macroscopically normal.Conclusion: Sugammadex does not appear to affect theprogesterone levels in pregnant rats in the first trimes-ter and the clinical course. Successful completion ofpregnancy and the absence of stillbirth or miscarriagewill guide future studies about the use of sugammadex,particularly in the first trimester of the pregnancy.

🔖

Bu Makaleye Atıf Yap

EROL, A., TAVLAN, A., KILIÇASLAN, A., TOPAL, A., TUNCER, S. U., ET, T. (2022). The Effects of sugammadex on progesterone levels in pregnant rats. Balkan Medical Journal, Cilt: 32 - Sayı: 2, 203–207. https://ajindex.com/articles/461377

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (5)

  1. Bom A, Bradley M, Cameron K, Clark JK, Van Egmond J, Feilden H, et al. A novel concept of reversing neuromuscu- lar block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetichost. Angew Chem Int Ed Engl 2002;41:266-70
  2. Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of ro- curonium bromide. Anesthesiology 2005;103:695-703. [CrossRef] 3. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-fnding and safety study. Anesthesiology 2006;104:667-74. [CrossRef] 4. Bom A, Clark JK, Palin R. New approaches to reversal of neuro- muscular block. Curr Opin Drug Discov Devel 2002;5:793-800
  3. Baillard C, Clec’h C, Catineau J, Salhi F, Gehan G, Cupa M, et al. Postoperative residual neuromuscular block: a survey of management. Br J Anaesth 2005;95:622-6. [CrossRef] 6. Bowman WC. Neuromuscular block. Br J Pharmacol 2006;147:277-86. [CrossRef] 7. European Medicines Agency. Available from: http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_Product_In- formation/human/000885/WC500052310.pdf
  4. Peplow PV. Effects of progesterone withdrawal on uterine pros- taglandin levels in the ovariectomized pregnant rat. Prostaglan- dins Leukot Essent Fatty Acids 1991;44:259-61. [CrossRef] 9. Bennett JP, Vallance DK, Vickery BH. The synchronization of ovulation in the adult female rat by oral administration of megestrol acetate. J Reprod Fertil 1968;16:159-63. [CrossRef] 10. Mirakhur RK. Sugammadex in clinicalpractice. Anaesthesia 2009,64:45-54. [CrossRef] 11. Hogg RM, Mirakhur RK. Sugammadex a selective relaxant binding agent for reversal of neuromuskuler block. Expert Rev Neurother 2009;9:599-608. [CrossRef] 12. Rezonja K, Sostaric M, Vidmar G, Mars T. Dexamethasone produces dose dependent inhibition of sugammadex reversal in in vitro innervated primary human muscle ells. Anesth Analg 2014;118:755-63. [CrossRef] 13. Eikermann M, Zaremba S, Malhotra A, Jordan AS, Rosowand C, Chamberlin NL. Neostigmine but not sugammadex impair supper airway dilato rmuscle activity and breathing. Br J An- aesth 2008;101:344-9. [CrossRef] 14. Kalkan Y, Tumkaya L, Bostan H, Tomak Y, Yılmaz A. Effects of sugammadex on immunoreactivity of calcineurin in rat tes- tes cell safter neuromuscular block: a pilot study. J Mol Histol 2011;9384-9
  5. Williamson RM